SI3021859T1 - Onkolitični adenovirusi, opremljeni s heterolognimi geni - Google Patents
Onkolitični adenovirusi, opremljeni s heterolognimi geni Download PDFInfo
- Publication number
- SI3021859T1 SI3021859T1 SI201430609T SI201430609T SI3021859T1 SI 3021859 T1 SI3021859 T1 SI 3021859T1 SI 201430609 T SI201430609 T SI 201430609T SI 201430609 T SI201430609 T SI 201430609T SI 3021859 T1 SI3021859 T1 SI 3021859T1
- Authority
- SI
- Slovenia
- Prior art keywords
- seq
- adenovirus according
- sequence
- adenovirus
- transgenic
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract 23
- 108090000623 proteins and genes Proteins 0.000 title claims 6
- 230000000174 oncolytic effect Effects 0.000 title claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 6
- 241000700605 Viruses Species 0.000 claims abstract 4
- 108700019146 Transgenes Proteins 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 3
- 230000009261 transgenic effect Effects 0.000 claims 10
- -1 ICOS Proteins 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 claims 2
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 102100030703 Interleukin-22 Human genes 0.000 claims 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 1
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 claims 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 1
- 102100024263 CD160 antigen Human genes 0.000 claims 1
- 108010046080 CD27 Ligand Proteins 0.000 claims 1
- 102000007499 CD27 Ligand Human genes 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 101710185679 CD276 antigen Proteins 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 claims 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 1
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 claims 1
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 claims 1
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 claims 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 102100034980 ICOS ligand Human genes 0.000 claims 1
- 101710093458 ICOS ligand Proteins 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 102000013691 Interleukin-17 Human genes 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010065637 Interleukin-23 Proteins 0.000 claims 1
- 108010066979 Interleukin-27 Proteins 0.000 claims 1
- 108010067003 Interleukin-33 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 102000000704 Interleukin-7 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 claims 1
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 claims 1
- 108060001084 Luciferase Proteins 0.000 claims 1
- 239000005089 Luciferase Substances 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 108010063312 Metalloproteins Proteins 0.000 claims 1
- 102000010750 Metalloproteins Human genes 0.000 claims 1
- 102100031789 Myeloid-derived growth factor Human genes 0.000 claims 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 claims 1
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 108700008625 Reporter Genes Proteins 0.000 claims 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 108700012920 TNF Proteins 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 102000015694 estrogen receptors Human genes 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 108010074109 interleukin-22 Proteins 0.000 claims 1
- 108090000237 interleukin-24 Proteins 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 235000009518 sodium iodide Nutrition 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (18)
- Onkolitični adenovirusi, opremeljeni s heterolognimi geni Patentni zahtevki1. Replikacijsko kompetenten onkolitični adenovirus skupine B, ki obsega zaporedje s formulo (I): 5 ’ITR-B ] -Ba-B2-Bx-Bb-B y-B3-3 ’ITR kjer: Bi obsega: E1A, E1B ali E1A-E1B; Ba obsega: -E2B-L1-L2-L3-E2A-L4; B2 je vez ali obsega: E3; Bx je vez ali DNA zaporedje, ki obsega: restrikcijsko mesto, enega ali več transgenov ali oba; Bb obsega L5; By obsega transgensko kaseto, ki obsega transgen in spojitveno ("splice") akceptorsko zaporedje; in B3 je vez ali obsega: E4, kjer je transgenska kaseta pod kontrolo endogenega promotorja, izbranega iz skupine, ki jo sestavljata E4 in poglavitni pozni promotor, in kjer transgenska kaseta obsega terapevtski gen, ki kodira material, izbran iz skupine, ki jo sestavljajo RNAi zaporedje, protein, protitelo ali njegov vezavni fragment, kemokin, citokin, imunomodulator in encim.
- 2. Replikacijsko kompetenten adenovirus po zahtevku 1, kjer je promotor poglavitni pozni promotor.
- 3. Replikacijsko kompetenten adenovirus po zahtevku 1 ali 2, kjer BY tudi obsega zaporedje, prikazano v SEQ ID NO: 11, ali DNA zaporedje, ki hibridizira nanj pod ostrimi pogoji.
- 4. Replikacijsko kompetenten adenovirus po katerem koli od zahtevkov od 1 do 3, kjer je spojitveni ("splice") akceptor izbran izmed CAGG, SEQ ID NO: 17 in SEQ ID NO: 18.
- 5. Replikacijsko kompetenten adenovirus po katerem koli od zahtevkov od 1 do 4, kjer transgenska kaseta nadalje obsega interno ribosomsko vstopno zaporedje ali 2A peptid z visoko samo-cepitveno učinkovitostjo.
- 6. Replikacijsko kompetenten adenovirus po katerem koli od zahtevkov od 1 do 5, kjer transgen nadalje obsega Kozak zaporedje.
- 7. Adenovirus po katerem koli od zahtevkov od 1 do 6, kjer transgenska kaseta nadalje obsega poliadenilacijsko zaporedje.
- 8. Adenovirus po katerem koli od zahtevkov od 1 do 7, kjer transgenska kaseta nadalje obsega restrikcijsko mesto na 3' koncu DNA zaporedja in/ali na 5' koncu DNA zaporedja.
- 9. Adenovirus po katerem koli od zahtevkov od 1 do 8, kjer vsaj ena transgenska kaseta kodira monocistronsko mRNA ali policistronsko mRA.
- 10. Adenovirus po zahtevku od 1 do 9, kjer je protitelo ali njegov vezavni fragment specifičen za 0X40, 0X40 ligand, CD27, CD28, CD30, CD40, CD40 ligand, CD70, CD137, GITR, 4-1BB, ICOS, ICOS ligand, CTLA-4, PD-1, PD-L1, PD-L2, VISTA, B7-H3, B7-H4, HVEM, ILT-2, ILT-3, ILT-4, TIM-3, LAG-3, BTLA, LIGHT, CD160, CTLA-4, PD-1, PD-L1, PD-L2.
- 11. Adenovirus po katerem koli od zahtevkov od 1 do 10, kjer je kodirani protein citokin, neodvisno izbran iz skupine, ki jo sestavljajo IL-la, IL-Ιβ, IL-6, IL-9, IL-12, IL-13, IL-17, IL-18, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-33, IL-35, IL-2, IL-4, IL-5, IL-7, IL-10, IL-15, IL-21, IL-25, IL-1RA, IFNa, IFNp, IFNy, TNFa, TGFp, limfotoksin a (LTA) in GM-CSF.
- 12. Adenovirus po katerem koli od zahtevkov od 1 do 11, kjer je kodirani protein kemokin, neodvisno izbran iz skupine, ki jo sestavljajo IL-8, CCL5, CCL17, CCL20, CCL22, CXCL9, CXCL10, CXCL11, CXCL13, CXCL12, CCL2, CCL19, CCL21, CXCR2, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CXCR3, CXCR4, CXCR5 in CRTH2.
- 13. Adenovirus po katerem koli od zahtevkov od 1 do 12, kjer je transgen reporterski gen, na primer natrijev jodid simporter, intracelulami metaloproteini, HSVl-tk, GFP-ji, luciferaza ali estrogenski receptor.
- 14. Adenovirus po katerem koli od zahtevkov od 1 do 13, kjer je adenovirus Adi 1.
- 15. Adenovirus po katerem koli od zahtevkov od 1 do 13, kjer je adenovirus virus, znan kot EnAd, prikazan v zaporedju ID No: 12.
- 16. Adenovirus po katerem koli od zahtevkov 1 do 15, kjer virus obsega zaporedje s SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69 ali SEQ ID NO: 73.
- 17. Sestavek, ki obsega adenovirus po katerem koli od zahtevkov od 1 do 16.
- 18. Adenovirus po katerem koli od zahtevkov od 1 do 16 ali sestavek po zahtevku 17 za uporabo v zdravljenju.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201318885A GB201318885D0 (en) | 2013-10-25 | 2013-10-25 | Adenovirus |
| GBGB1318880.0A GB201318880D0 (en) | 2013-10-25 | 2013-10-25 | Adenovirus |
| GBGB1322851.5A GB201322851D0 (en) | 2013-12-23 | 2013-12-23 | Method |
| GB201401159A GB201401159D0 (en) | 2014-01-23 | 2014-01-23 | Adenovirus |
| GB201406470A GB201406470D0 (en) | 2014-04-10 | 2014-04-10 | Virus |
| PCT/EP2014/072919 WO2015059303A1 (en) | 2013-10-25 | 2014-10-24 | Oncolytic adenoviruses armed with heterologous genes |
| EP14799117.8A EP3021859B1 (en) | 2013-10-25 | 2014-10-24 | Oncolytic adenoviruses armed with heterologous genes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3021859T1 true SI3021859T1 (sl) | 2018-04-30 |
Family
ID=51900851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201430609T SI3021859T1 (sl) | 2013-10-25 | 2014-10-24 | Onkolitični adenovirusi, opremljeni s heterolognimi geni |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US9987314B2 (sl) |
| EP (3) | EP3372236A1 (sl) |
| KR (1) | KR102272932B1 (sl) |
| CN (2) | CN108064159B (sl) |
| AU (1) | AU2014338864C1 (sl) |
| CA (2) | CA3183645A1 (sl) |
| CL (1) | CL2016000959A1 (sl) |
| CY (1) | CY1119955T1 (sl) |
| DK (1) | DK3021859T3 (sl) |
| EA (1) | EA036414B1 (sl) |
| ES (1) | ES2661132T3 (sl) |
| HR (1) | HRP20180317T1 (sl) |
| HU (1) | HUE035875T2 (sl) |
| IL (2) | IL244944B (sl) |
| LT (1) | LT3021859T (sl) |
| MX (1) | MX2016005170A (sl) |
| MY (1) | MY175614A (sl) |
| NO (1) | NO3021859T3 (sl) |
| NZ (1) | NZ718931A (sl) |
| PE (1) | PE20160951A1 (sl) |
| PH (1) | PH12016500759B1 (sl) |
| PL (1) | PL3021859T3 (sl) |
| PT (1) | PT3021859T (sl) |
| RS (1) | RS57043B1 (sl) |
| SA (1) | SA516371011B1 (sl) |
| SG (2) | SG10201804030WA (sl) |
| SI (1) | SI3021859T1 (sl) |
| TR (1) | TR201802728T4 (sl) |
| WO (1) | WO2015059303A1 (sl) |
| ZA (1) | ZA201603646B (sl) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3007711B1 (en) | 2013-06-14 | 2020-10-21 | Psioxus Therapeutics Limited | A dosing regime and formulations for type b adenoviruses |
| HUE035875T2 (hu) | 2013-10-25 | 2018-06-28 | Psioxus Therapeutics Ltd | Heterológ géneket tartalmazó onkolitikus adenovírusok |
| GB201406608D0 (en) * | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| GB201510197D0 (en) | 2014-06-12 | 2015-07-29 | Psioxus Therapeutics Ltd | Method of treating ovarian cancer |
| WO2016030489A2 (en) | 2014-08-27 | 2016-03-03 | Psioxus Therapeutics Limited | A process for the production of adenovirus |
| CA2977350C (en) | 2015-02-20 | 2022-08-23 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| JP6879932B2 (ja) | 2015-04-06 | 2021-06-02 | サイトイミューン セラピューティクス， インコーポレイテッドＣｙｔｏｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ | 神経膠芽腫のためのｅｇｆｒ指向ｃａｒ療法 |
| KR102643574B1 (ko) * | 2015-04-30 | 2024-03-06 | 싸이오서스 테라퓨틱스 엘티디. | B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스 |
| MY193281A (en) * | 2015-12-17 | 2022-09-30 | Psioxus Therapeutics Ltd | Group b adenovirus encoding an anti-tcr-complex antibody or fragment |
| ES2831080T5 (es) | 2016-01-08 | 2023-10-30 | Replimune Ltd | Virus oncolítico modificado |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| CA3033267A1 (en) | 2016-08-29 | 2018-03-08 | Psioxus Therapeutics Limited | Adenovirus armed with bispecific t cell engager (bite) |
| WO2018083257A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083258A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018083259A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| GB201700350D0 (en) * | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| WO2018170763A1 (zh) * | 2017-03-22 | 2018-09-27 | 深圳市博奥康生物科技有限公司 | ILA 基因的 RNAi 表达载体及其构建方法和应用 |
| TWI796329B (zh) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
| WO2018220207A1 (en) * | 2017-06-01 | 2018-12-06 | Psioxus Therapeutics Limited | Oncolytic virus and method |
| JP7403444B2 (ja) | 2017-10-20 | 2023-12-22 | エフ． ホフマン－ラ ロシュ アーゲー | 抗体の複写保護措置 |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
| AU2019299555A1 (en) * | 2018-07-04 | 2021-02-25 | Cytoimmune Therapeutics, Inc. | Compositions and methods for immunotherapy targeting FLT3, PD-1, and/or PD-L1 |
| SG11202100023XA (en) | 2018-07-11 | 2021-01-28 | Actym Therapeutics Inc | Engineered immunostimulatory bacterial strains and uses thereof |
| JP2022502074A (ja) * | 2018-09-10 | 2022-01-11 | ジェネセイル バイオテック（シャンハイ）カンパニー リミテッド | 改変された腫瘍溶解性ウイルス、組成物、およびその使用 |
| US11542526B2 (en) * | 2019-02-21 | 2023-01-03 | Unleash Immuno Oncolytics, Inc. | Oncolytic adenoviral vector and methods of use |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| EP3931210A1 (en) | 2019-02-27 | 2022-01-05 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| GB201909081D0 (en) | 2019-06-25 | 2019-08-07 | Psioxus Therapeutics Ltd | Method |
| BR112022009139A2 (pt) | 2019-11-12 | 2022-09-06 | Actym Therapeutics Inc | Plataformas de dispensação de bactérias imunoestimuladoras e seu uso para dispensação de produtos terapêuticos |
| KR20210118757A (ko) * | 2020-03-23 | 2021-10-01 | (주)큐리진 | STAT3 및 mTOR를 이중 특이적으로 표적하는 핵산서열을 포함한 항암 바이러스 |
| KR20210118760A (ko) * | 2020-03-23 | 2021-10-01 | (주)큐리진 | AR 및 mTOR를 이중 특이적으로 표적하는 핵산분자를 포함하는 항암바이러스 |
| KR102601875B1 (ko) * | 2020-03-25 | 2023-11-14 | (주)큐리진 | 면역 회피성 항종양 아데노바이러스 |
| JP2023539454A (ja) | 2020-08-12 | 2023-09-14 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム |
| CN114717203B (zh) * | 2020-12-22 | 2023-06-27 | 广东东阳光药业有限公司 | 一种hIL7/hCCL19双基因重组溶瘤病毒及其制备方法和用途 |
| AU2021410765A1 (en) * | 2020-12-22 | 2023-07-13 | Ensoma, Inc. | Adenoviral gene therapy vectors |
| GB202102049D0 (en) | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
| CA3235418A1 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| WO2023168436A1 (en) * | 2022-03-03 | 2023-09-07 | Board Of Regents, The University Of Texas System | Anti-cd19 and anti-cd79b chimeric antigen receptors and methods of use thereof |
| CN116836283B (zh) * | 2022-05-17 | 2024-05-07 | 苏州万灏生物科技有限公司 | 具有多种免疫调节因子的增强型溶瘤病毒及其制备方法和应用 |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0170269A3 (en) | 1984-08-02 | 1987-09-23 | Kao Corporation | Medicated cosmetic compositions |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| CN1115414C (zh) | 1993-07-13 | 2003-07-23 | 罗纳-布朗克罗莱尔股份有限公司 | 用于基因治疗的病毒载体 |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US5677170A (en) | 1994-03-02 | 1997-10-14 | The Johns Hopkins University | In vitro transposition of artificial transposons |
| FR2730504B1 (fr) * | 1995-02-13 | 1997-03-28 | Rhone Poulenc Rorer Sa | Procede de preparation de genomes d'adenovirus recombinants |
| DE19648650C2 (de) | 1996-01-29 | 1998-07-02 | Schering Ag | Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| US5877011A (en) | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
| CN1242051A (zh) | 1996-12-31 | 2000-01-19 | 昂尼克斯药物公司 | 用于肿瘤治疗和预防的致细胞病变病毒 |
| WO1998037205A1 (en) | 1997-02-20 | 1998-08-27 | The John Hopkins University School Of Medicine | Mutations in atp-dependent transposition proteins that reduce target-site specificity |
| CN101618049A (zh) | 1997-10-09 | 2010-01-06 | 威尔斯塔特生物公司 | 使用病毒来治疗赘生物 |
| US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US6291214B1 (en) | 1998-05-11 | 2001-09-18 | Glaxo Wellcome Inc. | System for generating recombinant viruses |
| US20020019051A1 (en) | 1998-05-27 | 2002-02-14 | Monika Lusky | Chimeric adenoviral vectors |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| CN1110553C (zh) | 1998-07-15 | 2003-06-04 | 杭州赛狮生物技术开发有限公司 | 基因工程腺病毒及其用途 |
| CA2341061A1 (en) * | 1998-08-27 | 2000-03-09 | Aventis Pharma S.A. | Targeted adenovirus vectors for delivery of heterologous genes |
| CA2342396A1 (en) | 1998-09-11 | 2000-03-23 | Genvec, Inc. | Alternatively targeted adenovirus |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| CA2354024C (en) | 1998-12-09 | 2009-12-22 | Jeffrey Schlom | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| DE60029195T2 (de) | 1999-02-22 | 2007-06-28 | Transgene S.A. | Verfahren zur Gewinnung von purifizierter Virenzusammensetzung |
| CA2364562A1 (fr) | 1999-04-09 | 2000-10-19 | Aventis Pharma S.A. | Composition destinee a la conservation d'adenovirus recombinants infectieux |
| ATE485382T1 (de) | 1999-05-17 | 2010-11-15 | Crucell Holland Bv | Rekombinantes adenovirus des ad26-serotyps |
| AU5464000A (en) | 1999-06-01 | 2000-12-18 | University Of Washington | Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins |
| JP4827353B2 (ja) | 1999-08-09 | 2011-11-30 | ターゲティッド ジェネティクス コーポレイション | 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大 |
| US7396679B2 (en) | 1999-11-15 | 2008-07-08 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| EP1568779A1 (en) | 2000-01-21 | 2005-08-31 | BioVex Limited | HSV strains for the oncolytic treatment of cancer |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| WO2001092549A2 (en) | 2000-05-31 | 2001-12-06 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
| WO2001094413A2 (en) | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| AU2002217721A1 (en) | 2001-01-04 | 2002-07-16 | Kristina Lindman | Viral vector for gene therapy |
| US20050175589A1 (en) | 2001-07-13 | 2005-08-11 | Btg International Limited | Anti-neoplastic viral agents |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| AU2003206815A2 (en) | 2002-02-01 | 2003-09-02 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with PODs |
| US20060147420A1 (en) | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| AU2003223775A1 (en) | 2002-04-30 | 2003-11-17 | Duke University | Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use |
| WO2004051268A1 (en) | 2002-12-03 | 2004-06-17 | Celltech R & D Limited | Assay for identifying antibody producing cells |
| US20040167088A1 (en) | 2003-02-25 | 2004-08-26 | Genvec, Inc. | Method of using adenoviral vectors with increased persistence in vivo |
| US20040213764A1 (en) | 2003-03-28 | 2004-10-28 | William Wold | Adenovirus replication-competent vectors expressing trail |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| PL1644412T5 (pl) | 2003-07-01 | 2019-01-31 | Ucb Biopharma Sprl | Modyfikowane fragmenty Fab przeciwciała |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| EP1646717A4 (en) | 2003-07-18 | 2006-12-20 | Onyx Pharma Inc | ADENOVIRAL VECTORS OF SUB-GROUP B FOR THE TREATMENT OF DISEASES |
| US20050186178A1 (en) | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
| ES2358427T3 (es) | 2003-10-16 | 2011-05-10 | Micromet Ag | Elementos de unión a cd-3 desinmunizados multiespecíficos. |
| WO2005107474A2 (en) * | 2004-04-30 | 2005-11-17 | Introgen Therapeutics, Inc. | Oncolytic adenovirus armed with therapeutic genes |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| MXPA06013570A (es) * | 2004-05-26 | 2007-02-08 | Schering Ag | Adenovirus quimericos para usarse en el tratamiento del cancer. |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| US20060292682A1 (en) | 2004-07-22 | 2006-12-28 | Hawkins Lynda K | Addition of transgenes into adenoviral vectors |
| EP1784493A2 (en) | 2004-09-01 | 2007-05-16 | The Government of the United States of America as Represented by The Department of Health and Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
| US20090208924A1 (en) | 2004-12-01 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Generation of Replication Competent Viruses for Therapeutic Use |
| US20060205080A1 (en) | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
| AU2006284756B2 (en) | 2005-08-31 | 2012-06-07 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| CN1961961B (zh) | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| DE102005055128B4 (de) | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
| ES2304281B1 (es) | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| CA2673520A1 (en) | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
| EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
| US20110034560A1 (en) | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| US20110086005A1 (en) | 2008-05-27 | 2011-04-14 | Oncolytics Biotech Inc. | Modulating interstitial pressure and oncolytic viral delivery and distribution |
| CA2737241C (en) | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
| BRPI0919840B1 (pt) | 2008-10-01 | 2023-02-28 | Amgen Research (Munich) Gmbh | Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende |
| ES2385251B1 (es) * | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| WO2011043719A1 (en) | 2009-10-05 | 2011-04-14 | Ya-Fang Mei | Replicating viral vectors for gene therapy |
| KR101957616B1 (ko) | 2010-08-16 | 2019-03-12 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 아데노바이러스 조립 방법 |
| AU2011306845C1 (en) | 2010-09-24 | 2015-05-14 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - CTLA - 4 antibodies |
| AU2012298537B2 (en) | 2011-08-23 | 2017-08-10 | Roche Glycart Ag | Bispecific T cell activating antigen binding molecules |
| US20140316369A1 (en) | 2011-11-14 | 2014-10-23 | Regenerative Sciences, Llc | Suspended particle delivery systems and methods |
| CN102586327B (zh) | 2012-01-18 | 2013-09-11 | 陕西师范大学 | 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用 |
| HUE044612T2 (hu) | 2012-05-04 | 2019-11-28 | Pfizer | Prosztata-asszociált antigének és vakcina-alapú immunterápiás rendek |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| EP2964241A1 (en) | 2013-03-05 | 2016-01-13 | Baylor College Of Medicine | Oncolytic virus |
| WO2015040234A1 (en) | 2013-09-23 | 2015-03-26 | Crucell Holland B.V. | Adenovirus formulations |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| GB201318793D0 (en) | 2013-10-24 | 2013-12-11 | Plaquetec Ltd | Vascular Biomarkers |
| HUE035875T2 (hu) * | 2013-10-25 | 2018-06-28 | Psioxus Therapeutics Ltd | Heterológ géneket tartalmazó onkolitikus adenovírusok |
| JP2016540505A (ja) | 2013-11-22 | 2016-12-28 | ディーエヌエートリックス インコーポレイテッド | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
| US10400038B2 (en) | 2014-04-03 | 2019-09-03 | Igm Biosciences, Inc. | Modified J-chain |
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| WO2016030489A2 (en) | 2014-08-27 | 2016-03-03 | Psioxus Therapeutics Limited | A process for the production of adenovirus |
| GB201503500D0 (en) | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| KR102626276B1 (ko) | 2015-03-17 | 2024-01-17 | 틸트 바이오세러퓨틱스 오이 | 이-특이적인 항체를 암호화하는 종양붕괴성 아데노바이러스 및 이와 관련된 방법 및 용도 |
| KR102643574B1 (ko) | 2015-04-30 | 2024-03-06 | 싸이오서스 테라퓨틱스 엘티디. | B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스 |
| MY193281A (en) | 2015-12-17 | 2022-09-30 | Psioxus Therapeutics Ltd | Group b adenovirus encoding an anti-tcr-complex antibody or fragment |
| CA3033267A1 (en) | 2016-08-29 | 2018-03-08 | Psioxus Therapeutics Limited | Adenovirus armed with bispecific t cell engager (bite) |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| SG11201903407XA (en) | 2016-10-20 | 2019-05-30 | Alpine Immune Sciences Inc | Secretable variant immunomodulatory proteins and engineered cell therapy |
| WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083259A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
-
2014
- 2014-10-24 HU HUE14799117A patent/HUE035875T2/hu unknown
- 2014-10-24 CN CN201480062880.3A patent/CN108064159B/zh active Active
- 2014-10-24 EP EP17194455.6A patent/EP3372236A1/en active Pending
- 2014-10-24 TR TR2018/02728T patent/TR201802728T4/tr unknown
- 2014-10-24 DK DK14799117.8T patent/DK3021859T3/en active
- 2014-10-24 CA CA3183645A patent/CA3183645A1/en active Pending
- 2014-10-24 LT LTEP14799117.8T patent/LT3021859T/lt unknown
- 2014-10-24 PT PT147991178T patent/PT3021859T/pt unknown
- 2014-10-24 EP EP20210597.9A patent/EP3831398A1/en active Pending
- 2014-10-24 PL PL14799117T patent/PL3021859T3/pl unknown
- 2014-10-24 CA CA2927968A patent/CA2927968C/en active Active
- 2014-10-24 PE PE2016000536A patent/PE20160951A1/es unknown
- 2014-10-24 MY MYPI2016000623A patent/MY175614A/en unknown
- 2014-10-24 NZ NZ718931A patent/NZ718931A/en unknown
- 2014-10-24 SG SG10201804030WA patent/SG10201804030WA/en unknown
- 2014-10-24 EA EA201690545A patent/EA036414B1/ru unknown
- 2014-10-24 SG SG11201602887QA patent/SG11201602887QA/en unknown
- 2014-10-24 WO PCT/EP2014/072919 patent/WO2015059303A1/en active Application Filing
- 2014-10-24 US US15/031,716 patent/US9987314B2/en active Active
- 2014-10-24 RS RS20180246A patent/RS57043B1/sr unknown
- 2014-10-24 KR KR1020167013117A patent/KR102272932B1/ko active IP Right Grant
- 2014-10-24 MX MX2016005170A patent/MX2016005170A/es active IP Right Grant
- 2014-10-24 AU AU2014338864A patent/AU2014338864C1/en active Active
- 2014-10-24 EP EP14799117.8A patent/EP3021859B1/en active Active
- 2014-10-24 CN CN202111375653.4A patent/CN114457044A/zh active Pending
- 2014-10-24 ES ES14799117T patent/ES2661132T3/es active Active
- 2014-10-24 SI SI201430609T patent/SI3021859T1/sl unknown
- 2014-10-24 NO NO14799117A patent/NO3021859T3/no unknown
-
2016
- 2016-04-06 IL IL244944A patent/IL244944B/en active IP Right Grant
- 2016-04-21 CL CL2016000959A patent/CL2016000959A1/es unknown
- 2016-04-24 SA SA516371011A patent/SA516371011B1/ar unknown
- 2016-04-25 PH PH12016500759A patent/PH12016500759B1/en unknown
- 2016-05-25 ZA ZA2016/03646A patent/ZA201603646B/en unknown
-
2018
- 2018-02-21 HR HRP20180317TT patent/HRP20180317T1/hr unknown
- 2018-02-26 CY CY20181100227T patent/CY1119955T1/el unknown
- 2018-04-30 US US15/967,093 patent/US11439678B2/en active Active
-
2019
- 2019-09-12 IL IL269304A patent/IL269304B/en active IP Right Grant
-
2020
- 2020-12-23 US US17/247,787 patent/US11938159B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3021859T1 (sl) | Onkolitični adenovirusi, opremljeni s heterolognimi geni | |
| WO2015155370A4 (en) | Group b adenovirus modified in the e4orf4 region | |
| HRP20200439T1 (hr) | Onkolitički adenovirus koji kodira protein b7 | |
| JP2019502379A5 (sl) | ||
| Gallagher et al. | Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses | |
| Rothe et al. | Tumor necrosis factor receptors-structure and function | |
| JP2019534036A5 (sl) | ||
| JP2019508017A5 (sl) | ||
| JP2020520922A (ja) | Ｔ細胞療法を向上させるための、哺乳動物ｔ細胞の活性化により誘導可能な合成プロモーター（ｓｙｎ＋ｐｒｏ）の作製 | |
| Wahl et al. | IL-20 receptor 2 signaling down-regulates antigen-specific T cell responses | |
| JP2013516194A5 (sl) | ||
| CA3128350A1 (en) | Microenvironment sensors to regulate engineered gene expression | |
| WO2009140206A1 (en) | Improved expression of il-12 family heterodimers | |
| Stevens et al. | Biphasic transcriptional regulation of the interferon regulatory factor-1 gene by prolactin: involvement of gamma-interferon-activated sequence and Stat-related proteins. | |
| Ghorbaninezhad et al. | Tumor necrosis factor‑α in systemic lupus erythematosus: Structure, function and therapeutic implications | |
| Gould et al. | Inhibition of established collagen-induced arthritis with a tumour necrosis factor-α inhibitor expressed from a self-contained doxycycline regulated plasmid | |
| Ezernieks et al. | The Human IgE Germline Promoter is Regulated By Interleukin‐4, Interleukin‐13, Interferon‐α and Interferon‐γ Via an Interferon‐γ‐Activated Site and Its Flanking Regions | |
| US20240102047A1 (en) | An oncolytic virus vector coding for variant interleukin-2 (vIL-2) polypeptide | |
| ES2670894T3 (es) | Promotor derivado de un gen humano | |
| KR20220024495A (ko) | 종양용해성 아데노바이러스 및 체크포인트 억제제 조합 요법 | |
| Tao et al. | Interleukin-6 up-regulates the expression of interleukin-15 is associated with MAPKs and PI3-K signaling pathways in the human keratinocyte cell line, HaCaT | |
| KR20210042084A (ko) | Hspa8 유전자의 프로모터 | |
| Kuhnert et al. | Cloning, sequencing and partial functional characterization of the 5'region of the human p75 tumor necrosis factor receptor-encoding gene (TNF-R) | |
| US20230100000A1 (en) | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens | |
| Angkasekwinai et al. | TH17 cytokines: characteristics, regulation, and biological function |